Hélène Bouvaist
A5032218282- Pulmonary Hypertension Research and Treatments
- Congenital Heart Disease Studies
- Cardiac Structural Anomalies and Repair
- Cardiovascular Issues in Pregnancy
- Cardiac Valve Diseases and Treatments
- Acute Myocardial Infarction Research
- Mechanical Circulatory Support Devices
- Cardiovascular Function and Risk Factors
- Venous Thromboembolism Diagnosis and Management
- Heart Failure Treatment and Management
- Infective Endocarditis Diagnosis and Management
- Coronary Interventions and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrest and Resuscitation
- Cardiac Imaging and Diagnostics
- Cardiac Arrhythmias and Treatments
- Cardiovascular Conditions and Treatments
- Cardiovascular and Diving-Related Complications
- Vascular Anomalies and Treatments
- Liver Disease and Transplantation
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Acute Ischemic Stroke Management
- Chronic Myeloid Leukemia Treatments
- Peripheral Artery Disease Management
- Vascular anomalies and interventions
Centre Hospitalier Universitaire de Grenoble
2016-2025
Université Grenoble Alpes
2016-2025
Hôpital Albert Michallon
2010-2024
Actelion (Switzerland)
2023
Actelion (Germany)
2023
AstraZeneca (Brazil)
2023
Bayer (United States)
2023
Novartis (Switzerland)
2023
Société Française de Cardiologie
2014-2021
University Hospital of Zurich
2017
The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial.In a randomized, double-blind trial, we compared tenecteplase plus heparin placebo normotensive embolism. Eligible had right ventricular dysfunction on echocardiography or computed tomography, as well myocardial injury indicated by positive test for cardiac troponin I T. primary outcome was death hemodynamic decompensation (or collapse) within 7 days after randomization. main safety...
The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases precapillary PH have been reported in patients who chronic myelogenous leukemia treated with tyrosine kinase inhibitor dasatinib.This study was designed to describe incident dasatinib-associated registry. From approval dasatinib (November 2006) September 30, 2010, 9 by at time diagnosis were identified. At diagnosis, had moderate severe functional and hemodynamic impairment. No other...
Patients with severe pulmonary arterial hypertension (PAH) in New York Heart Association (NYHA) functional class (FC) III/IV have a poor prognosis, despite survival benefits being demonstrated intravenous epoprostenol. In this pilot study, the efficacy and safety of triple combination therapy regimen patients PAH was investigated. Data from newly diagnosed NYHA FC (n=19) initiated on upfront (intravenous epoprostenol, bosentan sildenafil) were collected retrospectively prospective registry....
AimsIncreased left ventricular wall thickness (LVWT) is a common finding in cardiology. It not known how often hereditary transthyretin-related familial amyloid cardiomyopathy (mTTR-FAC) responsible for LVWT. Several therapeutic modalities mTTR-FAC are currently clinical trials; thus, it important to establish the prevalence of TTR mutations (mTTR) and characteristics patients with mTTR-FAC.
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate long-term of patients with PAH categorized according to strategy. Methods: A retrospective analysis incident idiopathic, heritable, or anorexigen-induced enrolled French Pulmonary Hypertension Registry (January 2006 December 2018) was conducted. Survival assessed strategy: monotherapy, dual therapy, triple-combination therapy (two...
The current treatment algorithm for chronic thromboembolic pulmonary hypertension (CTEPH) as depicted in the 2022 European Society of Cardiology (ESC)/European Respiratory (ERS) guidelines on diagnosis and (PH) includes a multimodal approach combinations endarterectomy (PEA), balloon angioplasty (BPA) medical therapies to target major vessel vascular lesions, microvasculopathy. Today, BPA >1700 patients has been reported literature from centers Asia, US, also Europe; many more have treated...
Treatment for pulmonary arterial hypertension (PAH) has been underpinned by single-agent therapy to which concomitant drugs are added sequentially when pre-defined treatment goals not met.This retrospective analysis of real-world clinical data in 97 patients with newly diagnosed PAH (86% New York Heart Association functional class III-IV) explored initial dual oral combination bosentan plus sildenafil (n=61), tadalafil (n=17), ambrisentan (n=11) or (n=8).All regimens were associated...
This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.21 incident, right heart catheterisation-confirmed cases dasatinib-induced PAH were identified from French Pulmonary Hypertension Registry. Clinical and haemodynamic variables compared baseline last follow-up (median (range) 24 (1-81) months).Median age was 52 years 15 patients female (71%). 19 received dasatinib for chronic myelogenous leukaemia a median duration 42 (8-74)...
Cardiopulmonary fitness in congenital heart disease (CHD) decreases faster than the general population resulting impaired health-related quality of life (HRQoL). As standard care seems insufficient to encourage and maintain fitness, an early hybrid cardiac rehabilitation programme could improve HRQoL CHD. The QUALIREHAB multicentre, randomized, controlled trial evaluated implemented a 12-week centre- home-based programme, including multidisciplinary physical activity sessions. Adolescent...
Portopulmonary hypertension (PoPH) is diagnosed in 2‐6% of liver transplantation (LT) candidates. We studied outcomes candidates for LT suffering from PoPH. Data were collected retrospectively a prospective registry. Pulmonary hemodynamic variables at the time PoPH diagnosis, last evaluation before LT, and within 6 months beyond after LT. Forty‐nine patients (35 males, 48 ± 8 years) analyzed (median Model End‐Stage Liver Disease score 20). At baseline, mean pulmonary artery pressure (mPAP)...
Homeostatic turnover of the extracellular matrix conditions structure and function healthy lung. In lung transplantation, long-term management remains limited by chronic allograft dysfunction, an umbrella term used for a heterogeneous entity ultimately associated with pathological airway and/or parenchyma remodeling.This study assessed whether local cross-talk between pulmonary microbiota host cells is key determinant in control lower remodeling posttransplantation.Microbiota DNA total RNA...